Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (ATRA): 7 pipeline candidates · 2 upcoming catalysts · ~9 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
9.3 months
D/E -1.54 · 65% dilution
Lead: Approved
7 candidates
2 upcoming, next in ~1505d
1 buy · 12 sells (180d)
A transparent, data-derived signal for Atara Biotherapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$83.0M
Cash
$8.4M
Quarterly Burn
$3.1M
Runway
9.3 mo
Revenue
$516K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| ATA3219 | Phase 1 |
| ATA3431 | Phase 1 |
| cefepime | Approved |
| ebvallo | — |
| tab-cel | Phase 3 |
| Tab-cel (Ebvallo) | Phase 3 |
| tabelecleucel | Phase 3 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
30
Total value held
$8.8M
| Holder | Shares | Value |
|---|---|---|
| adage capital partners gp, l.l.c. | 700,000 | $3.3M |
| vanguard capital management llc | 435,724 | $2.1M |
| mackenzie financial corp | 313,620 | $1.5M |
| blackrock, inc. | 79,022 | $374K |
| geode capital management, llc | 66,146 | $313K |
| staley capital advisers inc | 50,000 | $237K |
| millennium management llc | 47,689 | $226K |
| jane street group, llc | 33,870 | $160K |
| vanguard fiduciary trust co | 33,621 | $159K |
| bridgeway capital management, llc | 32,691 | $155K |
Showing top 10 of 30 institutional holders of Atara Biotherapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Atara Biotherapeutics, Inc.'s pipeline?
Atara Biotherapeutics, Inc. (ATRA) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Atara Biotherapeutics, Inc.'s lead drug candidate?
Atara Biotherapeutics, Inc.'s most advanced tracked candidate is ATA3219 (Phase 1) for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
What is Atara Biotherapeutics, Inc.'s next catalyst?
Atara Biotherapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic " — expected August 1, 2030.
What is Atara Biotherapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Atara Biotherapeutics, Inc. has approximately 9.3 months of cash runway.
What is Atara Biotherapeutics, Inc.'s market capitalization?
Atara Biotherapeutics, Inc.'s market capitalization is approximately $83.0M.
Get the full picture on Atara Biotherapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.